A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Read more about A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Read more about A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Read more about Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Read more about CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Read more about Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Understanding the tumor immune microenvironment (TIME) for effective therapy. Read more about Understanding the tumor immune microenvironment (TIME) for effective therapy.
Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? Read more about Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?
Is autoimmunity the Achilles' heel of cancer immunotherapy? Read more about Is autoimmunity the Achilles' heel of cancer immunotherapy?
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Read more about A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Read more about The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
